Today, the CVP, Japan & Intercontinental of Edwards Lifesciences (EW), Huimin Wang, sold shares of EW for $4.5M.
Following Huimin Wang’s last EW Sell transaction on August 28, 2012, the stock climbed by 102.2%.
See today’s analyst top recommended stocks >>
Based on Edwards Lifesciences’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $907 million and quarterly net profit of $226 million. In comparison, last year the company earned revenue of $822 million and had a net profit of $170 million. EW’s market cap is $31.94B and the company has a P/E ratio of 45.86. Currently, Edwards Lifesciences has an average volume of 1.24M.
Based on 14 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $159.82, reflecting a 3.8% upside.
The insider sentiment on Edwards Lifesciences has been negative according to 110 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Huimin Wang’s trades have generated a -23.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care.
